<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">17674310</PMID>
<DateCompleted>
<Year>2007</Year>
<Month>09</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>12</Month>
<Day>03</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0022-1899</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>196</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2007</Year>
<Month>Sep</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of infectious diseases</Title>
<ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.</ArticleTitle>
<Pagination>
<MedlinePgn>692-8</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The immunogenicity of inactivated poliovirus vaccine (IPV) in developing countries is not well documented. This study compared the immune response to IPV with that to oral poliovirus vaccine (OPV) in Guatemalan infants.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">This was an open-label, randomized comparison of IPV only, OPV only, or IPV followed by OPV in Guatemalan public health clinics. Serum samples were tested for neutralizing antibodies, and stool samples were tested for Sabin strain polioviruses.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Seropositivity rates 2 months after 2 doses of IPV were 98%-100% for polio types 1, 2, and 3 and were 97.1%, 99.3%, and 92.1% for OPV-only recipients (P&lt;.001 for the response to type 3). One month after the third dose, 100% of IPV-only recipients had protective antibodies against all 3 types, compared with 99%, 100%, and 97% against polio types 1, 2, and 3 respectively, among recipients of OPV only. Infants who received IPV only had higher geometric mean titers than infants who received OPV only. Maternal antibodies lowered the final antibody responses to IPV but did not prevent the development of protective levels of antibody. Of 191 stool samples from infants who received IPV only, 5 (2.6%) were positive for poliovirus vaccine strains.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">IPV alone and IPV followed by OPV are safe and effective for Guatemalan infants.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Asturias</LastName>
<ForeName>Edwin J</ForeName>
<Initials>EJ</Initials>
<AffiliationInfo>
<Affiliation>Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dueger</LastName>
<ForeName>Erica L</ForeName>
<Initials>EL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Omer</LastName>
<ForeName>Saad B</ForeName>
<Initials>SB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Melville</LastName>
<ForeName>Arturo</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nates</LastName>
<ForeName>Silvia V</ForeName>
<Initials>SV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Laassri</LastName>
<ForeName>Majid</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chumakov</LastName>
<ForeName>Konstantin</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Halsey</LastName>
<ForeName>Neal A</ForeName>
<Initials>NA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>K01 TW006659</GrantID>
<Acronym>TW</Acronym>
<Agency>FIC NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2007</Year>
<Month>07</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Infect Dis</MedlineTA>
<NlmUniqueID>0413675</NlmUniqueID>
<ISSNLinking>0022-1899</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000914">Antibodies, Viral</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D006166">Guatemala</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011051">Poliomyelitis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011054">Poliovirus Vaccine, Inactivated</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011055">Poliovirus Vaccine, Oral</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017201">Virus Shedding</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2007</Year>
<Month>02</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2007</Year>
<Month>03</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2007</Year>
<Month>8</Month>
<Day>4</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2007</Year>
<Month>9</Month>
<Day>28</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2007</Year>
<Month>8</Month>
<Day>4</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">17674310</ArticleId>
<ArticleId IdType="pii">JID38299</ArticleId>
<ArticleId IdType="doi">10.1086/520546</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>